Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNFT GENFIT	$4.25 -1.6%	$3.90	$2.55 ▼ $6.42	$216.01M	1.14	3,968 shs	417 shs
MDWD MediWound	$17.39 -0.3%	$19.34	$14.14 ▼ $22.50	$188.49M	0.21	74,797 shs	72,921 shs
NRXP NRx Pharmaceuticals	$2.53 -3.4%	$2.99	$1.10 ▼ $6.01	$51.90M	1.59	346,251 shs	237,998 shs
RAPT Rapt Therapeutics	$10.72 +3.9%	$9.85	$5.67 ▼ $26.56	$170.67M	0.01	106,220 shs	45,873 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNFT GENFIT	-3.57%	+8.82%	+11.92%	-0.46%	+0.47%
MDWD MediWound	+0.52%	-6.99%	-13.10%	-14.26%	-7.48%
NRXP NRx Pharmaceuticals	+4.38%	+3.56%	-12.08%	-2.60%	+43.17%
RAPT Rapt Therapeutics	-4.62%	-2.64%	-11.79%	+50.33%	-47.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNFT GENFIT	2.1595 of 5 stars	3.5	3.0	0.0	3.2	0.0	0.0
MDWD MediWound	1.4758 of 5 stars	3.4	1.0	0.0	0.9	0.8	0.6
NRXP NRx Pharmaceuticals	3.1036 of 5 stars	3.6	5.0	0.0	2.2	0.8	0.6
RAPT Rapt Therapeutics	4.5357 of 5 stars	4.3	3.0	4.2	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNFT GENFIT	3.00	Buy	$9.00	111.81% Upside
MDWD MediWound	2.80	Moderate Buy	$32.25	85.45% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	1,026.48% Upside
RAPT Rapt Therapeutics	2.57	Moderate Buy	$21.57	101.23% Upside

Current Analyst Ratings Breakdown

Latest NRXP, GNFT, MDWD, and RAPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	GNFT GENFIT	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
8/19/2025	MDWD MediWound	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/19/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
8/12/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/11/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
8/8/2025	RAPT Rapt Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$51.00 ➝ $38.00
8/4/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
7/30/2025	RAPT Rapt Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$14.00
7/22/2025	RAPT Rapt Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$31.00
7/10/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNFT GENFIT	$76.77M	2.77	$0.07 per share	61.76	$1.50 per share	2.83
MDWD MediWound	$20.22M	9.30	N/A	N/A	$1.86 per share	9.35
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.80) per share	N/A
RAPT Rapt Therapeutics	$1.53M	115.89	N/A	N/A	$9.94 per share	1.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	-$30.22M	-$2.64	N/A	N/A	N/A	-142.18%	-96.71%	-39.73%	N/A
NRXP NRx Pharmaceuticals	-$25.13M	-$2.24	N/A	N/A	N/A	N/A	N/A	-550.94%	N/A
RAPT Rapt Therapeutics	-$129.87M	-$14.17	N/A	N/A	N/A	N/A	-67.92%	-59.59%	N/A

Latest NRXP, GNFT, MDWD, and RAPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2025	Q2 2025	NRXP NRx Pharmaceuticals	-$0.31	-$0.98	-$0.67	-$0.98	N/A	N/A
8/14/2025	Q2 2025	MDWD MediWound	-$0.55	-$1.23	-$0.68	-$1.23	$5.68 million	$5.71 million
8/7/2025	Q2 2025	RAPT Rapt Therapeutics	-$0.61	-$0.65	-$0.04	-$0.65	N/A	N/A
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNFT GENFIT	0.08	1.23	1.23
MDWD MediWound	N/A	1.48	1.99
NRXP NRx Pharmaceuticals	N/A	0.11	0.22
RAPT Rapt Therapeutics	N/A	13.25	13.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNFT GENFIT	2.24%
MDWD MediWound	46.83%
NRXP NRx Pharmaceuticals	4.27%
RAPT Rapt Therapeutics	99.09%

Insider Ownership

Company	Insider Ownership
GNFT GENFIT	4.20%
MDWD MediWound	9.20%
NRXP NRx Pharmaceuticals	19.00%
RAPT Rapt Therapeutics	2.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable
NRXP NRx Pharmaceuticals	2	19.81 million	16.05 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable

NRXP, GNFT, MDWD, and RAPT Headlines

Recent News About These Companies

Rapt Therapeutics (NASDAQ:RAPT) Receives $21.57 Average PT from Analysts

August 20 at 2:11 AM | americanbankingnews.com

Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet

August 18 at 10:56 AM | zacks.com

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Moderate Buy" from Analysts

August 18 at 2:28 AM | marketbeat.com

Rapt Therapeutics price target raised to $9 from $8 at UBS

August 12, 2025 | msn.com

Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross

August 12, 2025 | zacks.com

HC Wainwright Issues Optimistic Forecast for RAPT Earnings

August 12, 2025 | americanbankingnews.com

Rapt Therapeutics (NASDAQ:RAPT) Stock Rating Lowered by Wall Street Zen

August 11, 2025 | americanbankingnews.com

HC Wainwright Issues Positive Forecast for RAPT Earnings

August 11, 2025 | marketbeat.com

Rapt Therapeutics (NASDAQ:RAPT) Rating Lowered to Sell at Wall Street Zen

August 10, 2025 | marketbeat.com

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Rapt Therapeutics (RAPT) Expected to Announce Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade

August 1, 2025 | zacks.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded by JPMorgan Chase & Co. to "Neutral" Rating

July 31, 2025 | marketbeat.com

RAPT Therapeutics Unveils Plans for RPT904 Development

July 30, 2025 | theglobeandmail.com

Rapt Therapeutics upgraded to Neutral from Underweight at JPMorgan

July 30, 2025 | msn.com

JP Morgan Upgrades RAPT Therapeutics (RAPT)

July 30, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Raised to Hold at Wall Street Zen

July 26, 2025 | marketbeat.com

Q2 Earnings Forecast for RAPT Issued By Lifesci Capital

July 25, 2025 | marketbeat.com

LifeSci Capital Initiates Coverage of RAPT Therapeutics (RAPT) with Outperform Recommendation

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Coverage Initiated by Analysts at Lifesci Capital

July 23, 2025 | marketbeat.com

Rapt Therapeutics initiated with an Outperform at LifeSci Capital

July 23, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP, GNFT, MDWD, and RAPT Company Descriptions

GENFIT NASDAQ:GNFT

$4.25 -0.07 (-1.64%)

Closing price 03:20 PM Eastern

Extended Trading

$4.14 -0.11 (-2.57%)

As of 04:07 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

MediWound NASDAQ:MDWD

$17.39 -0.05 (-0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$17.40 +0.00 (+0.03%)

As of 07:50 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

NRx Pharmaceuticals NASDAQ:NRXP

$2.53 -0.09 (-3.44%)

Closing price 04:00 PM Eastern

Extended Trading

$2.56 +0.03 (+0.99%)

As of 07:43 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Rapt Therapeutics NASDAQ:RAPT

$10.72 +0.40 (+3.88%)

Closing price 04:00 PM Eastern

Extended Trading

$10.72 0.00 (-0.01%)

As of 05:14 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time